-continued

```
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
        35                  40                  45

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
    50                  55                  60

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
65                  70                  75                  80

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
                85                  90                  95

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
            100                 105                 110

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
        115                 120                 125

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
    130                 135                 140

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
145                 150                 155                 160

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
                165                 170                 175

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
            180                 185                 190

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
        195                 200                 205

Lys Ser Leu Ser Leu Ser Pro Gly Lys
    210                 215
```

1. An antigen binding construct comprising

a first antigen-binding polypeptide construct which monovalently and specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) antigen on a HER2-expressing cell;

a second antigen-binding polypeptide construct which monovalently and specifically binds a HER2 ECD4 (extracellular domain 4) antigen on a HER2-expressing cell;

first and second linker polypeptides, wherein the first linker polypeptide is operably linked to the first antigen-binding polypeptide construct, and the second linker polypeptide is operably linked to the second antigen-binding polypeptide construct;

and wherein the linker polypeptides are capable of forming a covalent linkage with each other.

2-35. (canceled)

36. The construct of claim **1**, wherein the construct is conjugated to a drug.

37. The construct of claim **36**, wherein the drug is maytansine (DM1).

38. (canceled)

39. A pharmaceutical composition comprising the construct of claim **1** and a pharmaceutical carrier.

40. The pharmaceutical composition of claim **39**, the pharmaceutical carrier comprising a buffer, an antioxidant, a low molecular weight molecule, a drug, a protein, an amino acid, a carbohydrate, a lipid, a chelating agent, a stabilizer, or an excipient.

41-42. (canceled)

43. A method of treating a subject having a HER2 expressing (HER2+) tumor, comprising administering to the subject an effective amount of the construct of claim **1**.

44. The method according to claim **43**, wherein the result of the treatment is shrinking the tumor, inhibiting growth of the tumor, increasing time to progression of the tumor, prolonging disease-free survival of the subject, decreasing metastases, increasing the progression-free survival of the subject, or increasing overall survival of the subject.

45. The method according to claim **43**, wherein the tumor is pancreatic cancer, head and neck cancer, gastric cancer, colorectal cancer, breast cancer, renal cancer, cervical cancer, ovarian cancer, endometrial cancer, uterine cancer, malignant melanoma, cancer of the pharynx, oral cancer or skin cancer.

46-59. (canceled)

60. A method of detecting or measuring HER2 in a sample comprising contacting the sample with the antigen binding construct according to claim **1** and detecting or measuring the bound complex.

61. A method of inhibiting, reducing or blocking HER2 signaling in a cell comprising administering an effective amount of the antigen binding construct according to claim **1** to the cell.

62. A method of killing or inhibiting the growth of a HER2-expressing tumor cell comprising contacting the cell with the antigen binding construct according to claim **1**.

63-67. (canceled)

68. A method of producing the constructs according to claim **1** comprising culturing a host cell under conditions suitable for expressing the antigen binding construct